This study will examine the risk of systemic malignancies in pediatric patients with atopic
dermatitis exposed to Elidel 1% cream.
- males and females
- greater than or equal to 2 years and less than or equal to 17 years at enrollment
- diagnosis of atopic dermatitis (confirmed by treating physician)
- applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks
- past or present history of systemic malignancy, skin malignancy, or
- past or present use of oral immunosuppressive therapy